Abstract: The invention is directed to a process for recovering/purifying (meth)acrylic acid which does not use azeotropic solvent and is based on the use of two columns for purifying a reaction mixture comprising (meth)acrylic acid. The process according to the invention includes a dry vacuum pump condensation system, which makes it possible to reduce the amount of final aqueous discharges.

Abstract: A process for the recovery of polymer-grade (meth)acrylic acid, in the absence of organic solvent, from a gaseous reaction mixture comprising (meth)acrylic acid obtained by gas-phase oxidation of a precursor of the (meth)acrylic acid, the process carried out in a plant comprising at least one dehydration column and one finishing column, being characterized by the presence of at least one chemical treatment agent targeted at reducing the content of residual aldehydes. (Meth)acrylic acid obtained according to the invention meets criteria of high quality allowing it to be used in the manufacture of acrylic polymers, in particular for superabsorbents. This grade is also known as glacial acrylic acid GAA.

Abstract: A medical protective gown comprising a gown body. A centrally located orifice passes through a central region of a front panel of the gown body. A tubular protective sleeve extends forward from the front panel of the gown body, the tubular protective sleeve being located circumscribing the centrally located orifice. A tubular protective sleeve distal end panel is located at a distal end of the tubular protective sleeve. The tubular sleeve is adapted to receive a stethoscope or any other desired medical instrument. A broadened interior pocket is assembled to an interior surface of the gown body to support an upper, broader portion of the stethoscope or other instrument. A flange can be included with the tubular protective sleeve and/or the broadened interior pocket to aid in attachment to the gown body. The tubular protective sleeve can include a sleeve contraction system to contract the protective sleeve.

Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.

Abstract: An aspect of the present disclosure provides run-time adaption of external properties controlling operation of applications. In one embodiment, a setup data is maintained indicating conditions and properties that control the operation of applications. Each property is associated with a corresponding condition in the setup data to indicate that the property is to be configured upon satisfaction of the corresponding condition. In response to determining that a specific condition indicated in the setup data has been satisfied, a set of properties that is associated with the determined condition is identified. The applications are then automatically configured to thereafter operate with the identified set of properties.

Abstract: The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease.

Abstract: A system and method to record and trace data exchanges between cooperating hardware unit operations and software unit operations, providing an efficient mechanism to trace back to a root cause point from an observed failure point in a series of executed instructions performed within a data processing system. A data debug memory records information pertaining to each system memory access performed by instructions executed by the hardware and software units into separate memory information blocks. Linked relationships are created between certain ones of the memory information blocks to represent data dependencies that occurred between the instructions. These linked relationships may then be utilized to generate lists that map the various data dependencies between the executed instructions.

Abstract: The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid.

Abstract: In accordance with an embodiment, described herein is a system and method for optimizing cloud infrastructure through client request classification in a cloud computing environment. The cloud infrastructure can include one or more high-compute infrastructure instances, and one or more standard-compute infrastructure instances. Each request received at a load balancer can be checked against a request classification cache, to determine whether the request has been classified, and if it has been classified, whether the request can be routed to a high-compute infrastructure instance or a standard-compute infrastructure instance based on a classification of the request. An unclassified request can be classified based on a plurality of request parameters, and threshold values derived from the cloud infrastructure; and can be stored in the request classification cache. Classified requests in the classification cache can be provided to a cloud vendor for use in optimizing the cloud infrastructure.

Abstract: A cooling system having a cooling chamber including a surface defining one or more openings. A surface is configured to hold at least one container. An access door provides access to the cooling chamber. A refrigeration system is configured to cool the cooling chamber by forcing cool airflow through the one or more openings in the surface. The airflow through each of the one or more openings may be similar.

Abstract: The present invention relates to the manufacture of biobased acrylic acid from glycerol as starting material, the term “biobased acid” indicating that the acrylic acid is essentially based on a carbon source of natural origin.

Abstract: The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.

Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.

Abstract: A beverage dispenser ingredient level detection system is disclosed. The system may include a container with a wall, a canister, a capsule, an infrared emitter, and an infrared receiver. The canister may be disposed within the container at a first distance from the wall and may be configured to hold a beverage ingredient. The capsule may be disposed on an interior surface of the wall. The infrared emitter and the infrared receiver may be disposed within the capsule and the infrared receiver may be configured to transmit infrared light rays and the infrared receiver may be configured to detect infrared light rays reflected by the beverage ingredient in the canister to determine whether a pre-determined amount of the beverage ingredient is within the canister. The capsule may absorb infrared light rays that are not indicative of whether the pre-determined amount of the beverage ingredient is within the canister.

Abstract: The invention is directed to a process for recovering/purifying (meth)acrylic acid which does not use azeotropic solvent and is based on the use of two columns for purifying a reaction mixture comprising (meth)acrylic acid. The process according to the invention includes a dry vacuum pump condensation system, which makes it possible to reduce the amount of final aqueous discharges.

Abstract: The present invention relates to a method for treating a dry eye syndrome using an alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also relates to an ophthalmic composition comprising a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.

Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.

Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.

Abstract: The invention relates to the production of (meth)acrylic acid, and to implementation of a step of condensing water contained in a recycled gas effluent and/or in the air feed in a (meth)acrylic acid production process, which further includes a process for purifying a reaction mixture comprising (meth)acrylic acid without using azeotropic solvent and based on the use of two distillation columns.

Abstract: The invention relates to the production of (meth)acrylic acid, and to implementation of a step of condensing water contained in a recycled gas effluent and/or in the air feed in a (meth)acrylic acid production process, which further includes a process for purifying a reaction mixture comprising (meth)acrylic acid without using azeotropic solvent and based on the use of two distillation columns.